Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: A nationwide claims-based investigation

Cancer

Volumn 120, Issue 4, 2014, Pages 555-561

  Cohn, Joshua A ^a   Vekhter, Benjamin ^b   Lyttle, Christopher ^b   Steinberg, Gary D ^a   Large, Michael C ^c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Urology of Indiana   (United States)

Author keywords

diagnosis; hematuria; insurance claim review; standards; urinary bladder neoplasms

Indexed keywords

DIAGNOSIS; HEMATURIA; INSURANCE CLAIM REVIEW; STANDARDS; URINARY BLADDER NEOPLASMS;

AGED; DELAYED DIAGNOSIS; FEMALE; HEMATURIA; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; URINARY BLADDER NEOPLASMS;

EID: 84893760808     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28416     Document Type: Article

References (30)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-241.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Scosyrev E, Trivedi D, Messing E,. Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol. 2010; 20: 404-408.
4. Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA,. Gender differences in stage distribution of bladder cancer. Urology. 2000; 55: 368-371. (Pubitemid 30110586)
5. Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000; 55: 876-880. (Pubitemid 30330791)
6. Degraff DJ, Matusik RJ,. Gender specific differences in bladder cancer. J Urol. 2012; 188: 10-11.
7. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009; 10: 351-369.
8. Micheli A, Mariotto A, Giorgi Rossi A, Gatta G, Muti P,. The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group. Eur J Cancer. 1998; 34 (14 spec no): 2271-2278. (Pubitemid 29036897)
9. Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005; 65: 1118-1125. (Pubitemid 40824902)
10. Konety BR, Joslyn SA,. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003; 170: 1765-1771. (Pubitemid 37254924)
11. Taub DA, Hollenbeck BK, Cooper KL, et al. Racial disparities in resource utilization for cystectomy. Urology. 2006; 67: 288-293. (Pubitemid 43189843)
12. Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010; 116: 5235-5242.
13. Sánchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB,. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 2003; 169: 110-115. (Pubitemid 35461564)
14. Lee CT, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006; 175: 1262-1267.
15. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr,. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003; 170 (4 pt 1): 1085-1087. (Pubitemid 37108084)
16. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS,. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer. 2009; 115: 988-996.
17. Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP,. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. BMJ Open. 2013; 3 (6): doi: 10.1136/bmjopen-2013-002861.
18. Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM,. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 2011; 185: 1631-1636.
19. Varkarakis MJ, Gaeta J, Moore RH, Murphy GP,. Superficial bladder tumor. Aspects of clinical progression. Urology. 1974; 4: 414-420.
20. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE,. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000; 163: 524-527. (Pubitemid 30060509)
21. Golin AL, Howard RS,. Asymptomatic microscopic hematuria. J Urol. 1980; 124: 389-391. (Pubitemid 10004781)
22. Mohr DN, Offord KP, Owen RA, Melton LJ 3rd,. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA. 1986; 256: 224-229. (Pubitemid 16097834)
23. Sultana SR, Goodman CM, Byrne DJ, Baxby K,. Microscopic haematuria: urological investigation using a standard protocol. Br J Urol. 1996; 78: 691-696. (Pubitemid 127748016)
24. Davis R, Jones JS, Barocas DA, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012; 188 (6 suppl): 2473-2481.
25. Bruyninckx R, Buntinx F, Aertgeerts B, Van Casteren V,. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. Br J Gen Pract. 2003; 53: 31-35. (Pubitemid 36040601)
26. Johnson EK, Daignault S, Zhang Y, Lee CT,. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008; 72: 498-502.
27. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol. 2010; 28: 500-503.
28. Henning A, Wehrberger M, Madersbacher S, et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int. 2013; 112: 68-73.
29. Hansen LG, Chang S,. Health Research Data for the Real World: The Thomson Reuters MarketScan Databases. 2011. www.truvenhealth.com/assets/2012-Truven- MarketScan-white-paper.pdf. Accessed October 5, 2013.
30. Donat SM,. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am. 2003; 30: 765-776. (Pubitemid 37485191)